COMED Presents Next-Generation Intracellular Delivery Platform at XI Malta Medical School Conference

COMED Therapeutics showcased technology designed to enable therapeutic antibodies to reach intracellular targets, contributing to scientific exchange and medical innovation in Malta.

COMED Therapeutics is honored to take part in the XI Malta Medical School Conference, a triennial meeting organized by the University of Malta that brings together leading clinicians, researchers, and international experts at the Mediterranean Conference Centre in Valletta.

Our Senior Research Scientist, Nadir Gül, PhD, presented COMED’s next-generation intracellular delivery platform—technology designed to give therapeutic antibodies reliable access to targets inside the cell. This work reflects COMED’s commitment to advancing treatments for diseases long considered beyond reach.

We are proud to contribute to a conference that strengthens scientific exchange, collaboration, and medical innovation in Malta and beyond.

Latest from COMED

COMED Named Finalist for Start-Up Business of the Year at the 2026 Malta Business Awards

COMED Therapeutics has been named one of three finalists for Start-Up Business of the Year at the 2026 Malta Business Awards.

COMED Hooks Increase PI-Positive Cells by 69% in CAPAN-2 Cells

An independent study in CAPAN-2 pancreatic cancer cells found 68.7% more PI-positive objects following treatment with COMED Hooks versus matched nLNP controls.

Beyond Tumor Control: Evidence of Cell-State Reprogramming

An independent proteomic analysis of COMED’s pancreatic cancer program provides evidence of cell-state reprogramming following treatment with COMED Hooks.